- Home
- LPLA vs TNGX Comparison
LPLA vs TNGX Comparison
Compare LPLA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPLA
- TNGX
- Stock Information
- Founded
- LPLA 1989
- TNGX 2014
- Country
- LPLA United States
- TNGX United States
- Employees
- LPLA N/A
- TNGX N/A
- Industry
- LPLA Investment Bankers/Brokers/Service
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LPLA Finance
- TNGX Health Care
- Exchange
- LPLA Nasdaq
- TNGX Nasdaq
- Market Cap
- LPLA 30.4B
- TNGX 351.2M
- IPO Year
- LPLA 2010
- TNGX N/A
- Fundamental
- Price
- LPLA $384.11
- TNGX $5.63
- Analyst Decision
- LPLA Strong Buy
- TNGX Strong Buy
- Analyst Count
- LPLA 14
- TNGX 6
- Target Price
- LPLA $379.79
- TNGX $12.20
- AVG Volume (30 Days)
- LPLA 644.3K
- TNGX 3.4M
- Earning Date
- LPLA 07-24-2025
- TNGX 08-06-2025
- Dividend Yield
- LPLA 0.31%
- TNGX N/A
- EPS Growth
- LPLA 9.05
- TNGX N/A
- EPS
- LPLA 14.44
- TNGX N/A
- Revenue
- LPLA $12,896,160,000.00
- TNGX $40,990,000.00
- Revenue This Year
- LPLA $29.17
- TNGX N/A
- Revenue Next Year
- LPLA $17.00
- TNGX N/A
- P/E Ratio
- LPLA $26.61
- TNGX N/A
- Revenue Growth
- LPLA 25.70
- TNGX 10.09
- 52 Week Low
- LPLA $187.19
- TNGX $1.03
- 52 Week High
- LPLA $390.23
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- LPLA 58.84
- TNGX 77.32
- Support Level
- LPLA $363.95
- TNGX $4.80
- Resistance Level
- LPLA $378.48
- TNGX $5.63
- Average True Range (ATR)
- LPLA 9.71
- TNGX 0.52
- MACD
- LPLA -0.18
- TNGX -0.03
- Stochastic Oscillator
- LPLA 96.05
- TNGX 83.33
About LPLA LPL Financial Holdings Inc.
LPL Financial Holdings is an independent broker/dealer that provides a platform of proprietary technology, brokerage, and investment advisory services to financial advisors and institutions. As of the end of 2024, the company had over 29,000 advisors on its platform managing $1.7 trillion of client assets. The company doesn't have material operations outside the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.